Molecular Medicine Infrastructure
Deterministic
Molecular Medicine Infrastructure
NomosLogic turns genomic and multi-omic complexity into governed, reproducible, clinically usable intelligence for health systems, research, individuals and families, payers, and pharma.
The same variant can appear differently across consumer DNA, clinical sequencing, and research systems. If that layer is unstable, every downstream interpretation is unstable.
<30s
Genome Resolution
1.76M+
Clinical Logic Objects
497K+
Hardy Bridge Mappings
23.7M+
Anchored Molecular Reference Assets
Why This Matters
Genomics does not have a data problem.
It has an infrastructure problem.
Sequencing is cheap. Interpretation is not. Clinical genomics still depends on fragmented reference data, inconsistent variant calls, and opaque reasoning layers that cannot be reproduced, audited, or defended under regulatory scrutiny.
Most systems treat cross-system variant mismatch as a formatting problem. It is not. It is a substrate problem. Without deterministic identity resolution, anchored evidence, and governed logic, every downstream output inherits the same fragility as the data underneath it.
NomosLogic was built for the layer beneath interpretation: resolve variant identity across systems, execute deterministic clinical logic, and return auditable results that can actually be trusted.
What Makes NomosLogic Different
Built for governed clinical and scientific use
NomosLogic resolves variant identity, anchors evidence, and executes deterministic clinical logic across consumer, clinical, payer, and research environments.
Same input, same output
Every molecular result is produced by deterministic logic, not probabilistic inference, so it is reproducible across runs, sites, and time.
Findings trace to source
Every variant, every call, every interpretation resolves to a canonical reference: ClinVar, CPIC, FDA, GWAS, Hardy Bridge. Never to an opaque prior.
Logic is governed and versioned
Clinical rules are structured, immutable objects. When logic changes, prior outputs can be re-derived bit-for-bit, nothing drifts silently.
Outputs are clinically defensible
Every result carries provenance, evidence lineage, and policy state, the record required for regulatory review, payer audit, and clinician trust.
One layer, seven execution verticals
The same substrate serves clinical genomics, pharma research, payer infrastructure, pharmacogenomics, research infrastructure, consumer genomics, and population health without forking the logic underneath.
This is the difference between generating more interpretation and building infrastructure that can actually be trusted.
Platform Proof
A molecular medicine substrate, not a point solution.
NomosLogic is powered by a production-scale infrastructure layer that includes:
23.7M+
Anchored Molecular Reference Assets
1.76M+
Structured Clinical Logic Objects
497K+
Hardy Bridge Variant Mappings
608+
FDA Drug-Gene Mandates
<30s
Deterministic Genome Resolution
<90s
Multi-Omic Fusion
These are not marketing surfaces. They are the substrate that makes deterministic molecular medicine possible.
Seven Execution Verticals
One molecular medicine infrastructure. Seven downstream verticals.
The same deterministic substrate serves every stakeholder that needs molecular data to be trustworthy, reproducible, and usable in production. From clinical bedside to national population health, the logic layer does not fork.
Clinical Genomics
Delivers deterministic variant interpretation, pharmacogenomic guidance, and audit-ready reporting inside the clinical workflow, with SMART on FHIR integration, full provenance, and rapid genome resolution.
Pharma Research
Supports disease modeling, evolutionary resistance analysis, and trial stratification with reproducible, mechanism-anchored logic and validator-gated research outputs.
Payer Infrastructure
Provides a structured evidence layer for utilization review, prior authorization, and population pharmacogenomics, grounded in FDA, CPIC, and ClinVar references rather than narrative rationale.
Pharmacogenomics
Ships enterprise PGx infrastructure covering FDA drug-gene mandates, star allele resolution, and CPIC-anchored guidance for medication optimization and adverse drug event reduction at member scale.
Research Infrastructure
Powers longitudinal cohort intelligence, distributed constraint architecture modeling, and validator-gated research artifacts through the PROTEUS evolutionary simulation engine and Study Dossier layer.
Consumer Genomics
Transforms consumer DNA files into governed, legible, clinically relevant molecular insight through the same resolution layer used across the platform.
Population Health
Supports national genome programs with continuous re-analysis as clinical evidence evolves, version-locked rule execution, multi-tenant sovereign deployment, and full provenance at cohort scale.
Engine Architecture
A deterministic engine stack built for real-world load
NomosLogic is composed of interoperable engines that resolve, map, govern, and execute molecular intelligence at scale. Each engine performs a defined role in a governed molecular medicine pipeline from variant resolution and evidence normalization to disease modeling and clinical execution.
COVENANT
Genome Resolution Engine
<130s
Resolution Time
38,324
Variants Classified
- Classifies variants into three states: Positive, Ruled Out, Uncertain
- 100% ACMG SF v3.2 secondary findings coverage
- Quality thresholds: GQ>=30, DP>=20
- Zero hallucination architecture
TRINITY
Multi-Omic Fusion Engine
<90s
Fusion Time
1.76M+
Clinical Logic Objects
- Fuses genomic variants with laboratory biomarkers under one governed schema
- Cross-references 1.76M+ structured clinical logic objects
- Pharmacogenomic recommendations with star alleles and PMID citations
- FHIR-native export to Epic and Cerner
PROTEUS
Evolutionary Discovery Engine
1,000
Benchmark Generations
130s
Benchmark Runtime
5,000
Extended Runs
23.7M+
Anchored Molecular Reference Assets
- Identifies deterministic convergence in genomic systems
- Reproduces the same constrained interaction patterns across independent runs
- In-memory execution across 23.7M+ anchored molecular reference assets
- k-anonymity enforced directly at the SQL layer
- Study Dossier production layer: validator-gated, AI-translated research artifacts with cryptographic provenance
ANCESTRAL ADAPTATION
Evolutionary Medicine Engine
8
Population Groups
497K+
Variants Screened
- Integrates evolutionary medicine directly into point-of-care logic
- gnomAD v4 population frequencies across 8 global ancestry groups
- Wright's Fst quantifies population differentiation per variant
- Suppresses false-positive alerts from common ancestral variants
The Compounding Loop
The infrastructure feeds the discovery.
Every genome resolved by COVENANT, every fusion executed by TRINITY, every simulation run by PROTEUS becomes fuel for a network of >190 cross-domain scientific agents. The infrastructure generates data. The discovery layer finds patterns no single discipline reaches. Verified findings flow back into the infrastructure. The loop compounds.
1. Infrastructure runs
COVENANT, TRINITY, PROTEUS, and Hardy Bridge process real clinical, research, and consumer data under deterministic rule execution.
2. Data compounds
Every run enriches the Hardy Bridge, structured clinical logic objects, and anchored molecular reference assets. The substrate gets denser.
3. Discovery layer explores
>190 cross-domain scientific agents mine the substrate for cross-disciplinary patterns no individual researcher or single model would reach.
4. Governed verifier gates
Every candidate finding clears a deterministic verifier before entering shared knowledge. No unverified claim compounds.
5. Findings feed infrastructure
Verified discoveries return to the substrate as new logic, new mappings, new evidence. The next infrastructure run is sharper than the last.
Recent Cross-Domain Findings
In a single session the network independently produced three cross-domain research proposals from different disciplines: a ferroptosis biomarker framework, a phase-separation GPX4 catalysis mechanism, and a selenocysteine-competent cell-free translation platform, generated autonomously and cross-validated internally.
See the Discovery LayerProprietary Translation Layer
The Hardy Bridge
A proprietary nomenclature translation layer with 497,335 enriched variant-to-phenotype mappings. Translates seamlessly between clinical nomenclature systems.
Translation at Scale
Global Deployment
Built for every genome, in every jurisdiction.
Ancestry-conditioned interpretation across every population, sovereign on-premises or in-region cloud deployment, and localized product surfaces. Active partner and investor interest across Asia Pacific and Europe.
Ancestry-aware by construction
Every engine reads genomic architecture within the patient's actual ancestral context. Evolutionary adaptations are not misclassified as disease.
Sovereign deployment
On-premises, in-region cloud, or hybrid. National genome programs run the substrate inside their own regulatory perimeter with full provenance.
Localized surfaces
Consumer and clinical product surfaces localize into the languages that partners and patients actually use, without forking the underlying logic layer.
Regulatory posture
SHA-3-512 provenance on every analytical step, SHA-256 at rest, deterministic re-derivation for FDA 510(k), IND, BLA, GDPR, and regional equivalents.
Architecture
Sovereign by Design
Pseudonymous Identity Bridge
Salted HMAC-based pseudonymous identity matching for cross-system linkage without exposing raw personal identifiers to the matcher.
Confidential Compute
Clinical logic executes inside AWS Nitro-backed private infrastructure with AES-256 encryption at rest, TLS 1.3 in transit, and k-anonymity enforced at the SQL layer. Patient data never crosses the public internet.
Cryptographic Audit Trail
Every clinical decision and disclosure is signed and logged. Disclosure events are immutable and audit-ready by design.
Deterministic molecular infrastructure for clinical and scientific use.
The future of molecular medicine will not be built on black-box clinical reasoning.
It will be built on deterministic infrastructure that is fast, governed, traceable, and reproducible under scrutiny. NomosLogic is building that layer.
Investing? Series A open. Investor materials and contact